- Home
- SRDX
SRDX
Surmodics Inc.
as 02-21-2025 4:00pm EST
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | EDEN PRAIRIE |
| Market Cap: | N/A | IPO Year: | 1998 |
| Target Price: | $43.00 | AVG Volume (30 days): | 293.7K |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.17 - $42.44 | Next Earning Date: | 01-30-2025 |
| Revenue: | $125,448,000 | Revenue Growth: | -9.23% |
| Revenue Growth (this year): | 6.47% | Revenue Growth (next year): | 4.99% |
Stock Insider Trading Activity of Surmodics Inc. (SRDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Arens Timothy J. | SRDX | Chief Financial Officer | Nov 26 '24 | Sell | $39.44 | 7,009 | $276,453.18 | 70,350 |
Latest Surmodics Inc. News
SRDX Breaking Stock News: Dive into SRDX Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Business Wire
19 days ago
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
Zacks
22 days ago
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
Zacks
23 days ago
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics
Zacks
23 days ago
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
Associated Press Finance
23 days ago
SurModics: Fiscal Q1 Earnings Snapshot
Business Wire
23 days ago
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
Zacks
a month ago
Here's Why You Should Add Surmodics Stock to Your Portfolio Now
Compare SRDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRDX Surmodics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.